Xarelto

Xarelto is a brand name of rivaroxaban, approved by the FDA in the following formulation(s):

XARELTO (rivaroxaban - tablet; oral)

• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: July 1, 2011
  
  Strength(s): 10MG ^[RLD]


• 
  Manufacturer: JANSSEN PHARMS
  
  Approval date: November 4, 2011
  
  Strength(s): 15MG, 20MG ^[RLD]

Has a generic version of Xarelto been approved?

No. There is currently no therapeutically equivalent version of Xarelto available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xarelto. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Substituted oxazolidinones and their use in the field of blood coagulation
  Patent 7,157,456
  Issued: January 2, 2007
  Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Röhrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
  Assignee(s): Bayer HealthCare AG
  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
  
  Patent expiration dates:
  
  
  • February 8, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Substituted oxazolidinones and their use in the field of blood coagulation
  Patent 7,585,860
  Issued: September 8, 2009
  Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Rohrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
  Assignee(s): Bayer Schering Pharma Aktiengesellschaft
  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
  
  Patent expiration dates:
  
  
  • December 11, 2020
    
    ✓ 
    Drug substance
  
  



• 
  Substituted oxazolidinones and their use in the field of blood coagulation
  Patent 7,592,339
  Issued: September 22, 2009
  Inventor(s): Straub; Alexander & Lampe; Thomas & Pohlmann; Jens & Rohrig; Susanne & Perzborn; Elisabeth & Schlemmer; Karl-Heinz & Pernerstorfer; Joseph
  Assignee(s): Bayer Schering Pharma Aktiengesellschaft
  The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I) processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.
  
  Patent expiration dates:
  
  
  • December 11, 2020
    
    ✓ 
    Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
  
  
  
  • December 11, 2020
    
    ✓ 
    Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • November 4, 2014 - REDUCE THE RISK OF STROKE AND SYSTEMIC EMBOLISM IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION.
  
  
  • July 1, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Xarelto Consumer Information (Drugs.com)
• Xarelto Consumer Information (Wolters Kluwer)
• Xarelto Consumer Information (Cerner Multum)
• Xarelto Advanced Consumer Information (Micromedex)
• Rivaroxaban Consumer Information (Wolters Kluwer)
• Rivaroxaban Consumer Information (Cerner Multum)
• Rivaroxaban Advanced Consumer Information (Micromedex)